We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Diagnostic Tools Unveiled at EuroMedLab Exhibition

By LabMedica International staff writers
Posted on 27 Jun 2017
Print article
Image: The Atellica1500 automated urinalysis system (Photo courtesy of Siemens Healthineers).
Image: The Atellica1500 automated urinalysis system (Photo courtesy of Siemens Healthineers).
A major international manufacturer of automated diagnostic instruments and point-of-care diagnostic products has changed its name, a change that was highlighted at the IFCC EuroMedLab Athens June 12-14, 2017, exhibition.

Siemens Healthineers (Erlangen, Germany), which is the separately managed healthcare business of Siemens AG (Munich, Germany) presented its latest Atellica Portfolio offerings at the Athens exhibition.

The Portfolio included: Atellica Solution (flexible, scalable, automation-ready immunoassay, and clinical chemistry analyzers), Atellica 1500 Automated Urinalysis System (fully digital, automated urinalysis system), Atellica NEPH 630 System (mid-volume, dedicated nephelometric system that simplifies specialty protein testing), Atellica COAG 360 System (fully automated high-volume coagulation system that unifies five testing methodologies), Atellica MDX 160 System (flexible, automated molecular system with maximum productivity for multiple sample types), and Atellica PM 1.0 Software (process management software to optimize lab operations through data analytics and visualization).

In addition, the Athens presentation featured the RAPIDComm Data Management System, which enables centrally managed point-of-care testing programs through a single customizable interface.

“The 2017 product display from Siemens Healthineers represents our focus on engineering success and pioneering healthcare,” said Franz Walt, president of laboratory diagnostics at Siemens Healthineers. “The Atellica portfolio epitomizes engineering excellence - with revolutionary innovations designed to give lab professionals control and simplicity so they can spend less time on operations and more time on driving better outcomes.”

“The informatics solutions from Siemens Healthineers are designed to address connectivity challenges to help position point-of-care testing programs for success,” said Peter Koerte, president of point-of-care diagnostics at Siemens Healthineers. “Through open connectivity to more than 150 devices from all leading point-of-care vendors, we deliver secure - yet flexible - connectivity options that increase both choice and performance for greater efficiency.”

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Unstirred Waterbath
HumAqua 5
New
Blood Gas and Chemistry Analysis System
Edan i500

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The breakthrough could result in a higher success rate using a simple oral swab test before IVF (Photo courtesy of Shutterstock)

POC Oral Swab Test to Increase Chances of Pregnancy in IVF

Approximately 15% of couples of reproductive age experience involuntary childlessness. A significant reason for this is the growing trend of delaying family planning, a global shift that is expected to... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.